Antibiotics developer Cempra Pharmaceuticals is one of three healthcare companies expected to go public this week. A total of eight initial public offerings are expected this week, according to Renaissance Capital, a Greenwich, Connecticut research firm specializing in initial public offerings. Besides Chapel Hill, North Carolina-based Cempra’s planned $86 million IPO, the other healthcare-related IPOs […]
The initial public offering Cempra Pharmaceuticals plans now has a price. The Chapel Hill, North Carolina drug development company, which has two clinical-stage antibacterial compounds targeting drug-resistant bacteria, expects to sell 6 million shares for between $11 and $13 per share, raising up to $78 million before fees and expenses, according to an updated registration […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Drug development company Cempra Pharmaceuticals plans to raise $86.2 million in an initial public offering to pay for late-stage clinical trials on a pair of novel antibiotic compounds targeting drug-resistant bacteria. The IPO filing comes a month after Chapel Hill, North Carolina-based Cempra announced positive phase 2 results for antibiotic candidate CEM-101, also called Solithromycin, […]
Cempra Pharmaceuticals‘ bacterial pneumonia drug candidate was demonstrated to be just as effective as a currently available antibiotic and more important, it posed less risk of causing adverse reactions. In announcing phase 2 clinical trial results for solithromycin today, Chapel Hill, North Carolina biotechnology company Cempra said the efficacy of its drug candidate was comparable […]
Cempra Pharmaceuticals, which is developing novel antibiotics targeting drug-resistant bacteria, has raised $5 million in financing, according to securities filings. The Chapel Hill, North Carolina-based company has two clinical stage antibacterial compounds; one of which is being developed to fight nasty skin infections, including MRSA. That compound, called TAKSTA, is set to enter phase 3 […]
The growing prevalence of drug-resistant bacteria means a rise in so-called superbugs with no antibiotics to treat them. Cempra Pharmaceuticals aims to bring new antibacterial weapons to that fight. The Chapel Hill, North Carolina-based pharmaceutical company has two clinical-stage drug candidates, including one for MRSA infections, that would each address the growing problem of antimicrobial […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.